Drug Trial Radar · NCT07682337
Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects
Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
74
Planned (sponsor's estimate)
Start
Jun 29, 2026
Primary completion
Jun 1, 2027
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- SCBIO Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety, tolerability, pharmacokinetics, and food effect of a new investigational medicine called SCB0020160 in healthy adult men. This is the first time SCB0020160 will be administered to humans. Healthy adult men aged 18 to 65 years who meet the study eligibility criteria. Study details Participants will be randomly assigned to receive either SCB0020160 or placebo. The study includes single-dose and multiple-dose treatment periods, as well as an assessment of the effect of food on the absorption of SCB0020160. Participants will undergo safety assessments including physical examinations, vital signs, ECGs, blood and urine tests, and monitoring of adverse events. The study will also assess how SCB0020160 is processed by the body. There is no direct health benefit expected from participation. The results may help determine safe dose levels and support future clinical development of SCB0020160.
Conditions
- Solid Tumor
- Obesity
- Idiopathic Pulmonary Fibrosis
Interventions
SCB0020160Drug
Single and multiple oral doses of SCB0020160 administered under fasting conditions. A food-effect evaluation following a single oral dose will be conducted in Part A Cohort 4.
PlaceboDrug
Matching placebo administered orally under the same dosing conditions as SCB0020160, including participation in the food-effect evaluation in Part A Cohort 4
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and frequency of adverse events, adverse drug reactions, serious adverse events, and serious adverse drug reactionsTime frame: From first dose through Post-Study Visit (up to Day 33)
- For Physical examination to evaluate General AppearanceTime frame: From first dose through Post-Study Visit (up to Day 33)
- For Physical examination to evaluate HEENTTime frame: From first dose through Post-Study Visit (up to Day 33)
- For Physical examination to evaluate Neck (incl Thyroid & Nodes)Time frame: From first dose through Post-Study Visit (up to Day 33)
- For Physical examination to evaluate CardiovascularTime frame: From first dose through Post-Study Visit (up to Day 33)
- For Physical examination to evaluate RespiratoryTime frame: From first dose through Post-Study Visit (up to Day 33)
- For Physical examination to evaluate GastrointestinalTime frame: From first dose through Post-Study Visit (up to Day 33)
- For Physical examination to evaluate RenalTime frame: From first dose through Post-Study Visit (up to Day 33)
- For Physical examination to evaluate NeurologicalTime frame: From first dose through Post-Study Visit (up to Day 33)
- For Physical examination to evaluate MusculoskeletalTime frame: From first dose through Post-Study Visit (up to Day 33)
- For Physical examination to evaluate SkinTime frame: From first dose through Post-Study Visit (up to Day 33)
- For Vital signs (body temperature (tympanic)Time frame: From first dose through Post-Study Visit (up to Day 33)
- For Vital signs (Pulse Rate)Time frame: From first dose through Post-Study Visit (up to Day 33)
- For Vital signs (Systolic/Diastolic blood pressure)Time frame: From first dose through Post-Study Visit (up to Day 33)
- For 12-lead ECG (electrocardiogram)Time frame: From first dose through Post-Study Visit (up to Day 33)
- For Clinical Laboratory Test which includes UrinalysisTime frame: From first dose through Post-Study Visit (up to Day 33)
- For Clinical Laboratory Test which includes the CoagulationTime frame: From first dose through Post-Study Visit (up to Day 33)
- For Clinical Laboratory Test which includes the Blood chemistryTime frame: From first dose through Post-Study Visit (up to Day 33)
- For Clinical Laboratory Test which includes the HematologyTime frame: From first dose through Post-Study Visit (up to Day 33)
- Pharmacokinetic Parameters of SCB0020160 for CmaxTime frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
- Pharmacokinetic Parameters of SCB0020160 for TmaxTime frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
- Pharmacokinetic Parameters of SCB0020160 for AUClastTime frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
- Pharmacokinetic Parameters of SCB0020160 for AUCinfTime frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
- Pharmacokinetic Parameters of SCB0020160 for t½Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
- Pharmacokinetic Parameters of SCB0020160 for CL/FTime frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
- Pharmacokinetic Parameters of SCB0020160 for Vz/FTime frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
- Pharmacokinetic Parameters of SCB0020160 for MRTTime frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research Pty Ltd Ground Floor, 21-24 North Terrace
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.